Payers like key traits of pragmatic clinical trials, but are wary of pharmaceutical companies and plan to carefully scrutinize this new, appealing type of evidence.
Ronald A. Cantrell, PhD
Advertisement
Articles by Ronald A. Cantrell, PhD
Advertisement
Latest Updated Articles
- Pragmatic Clinical Trials: US Payers' Views on Their Value
Published: May 10th 2013 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
Boosting RSV Vaccination in Older Adults Could Save Thousands
3
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
4
Real-World Data Key to Optimizing CAR T-Cell Therapy Delivery, Outcomes
5
